Navigation Links
UCB Launches Research Alliance with Harvard University

BOSTON and BRUSSELS, June 30, 2011 /PRNewswire/ -- UCB and Harvard University officially launched their innovative Research Alliance during a signing ceremony that took place in Boston last night in the presence of his Royal Highness Prince Philippe of Belgium.

(Photo: )

The Alliance creates a unique drug discovery bridge between industry and academia, with Harvard scientists continuing their research that holds potential for the development of new therapeutic modalities in clinical medicine. The strategy underlying the collaborative alliance is to advance ongoing Harvard research projects along the drug development pathway.

"Harvard's world-class academic research is an excellent fit with UCB's world-class antibody research and central nervous system (CNS) pharmacology," said Ismail Kola, President of UCB NewMedicines. "Both parties will learn from each other through the collaboration and a two-way exchange of ideas. Harvard will benefit from UCB's strengths and industry experience in drug discovery and development; while Harvard's exceptional research will complement UCB's internal expertise.''

The first research project funded under the Harvard-UCB alliance is a collaboration with Professor Gokhan S. Hotamisligil, M.D., Ph.D., Chair, Department of Genetics and Complex Diseases, Harvard School of Public Health, to generate and develop antibodies against an exciting target with potential application in a range of diseases including diabetes and metabolic disorders.

"We couldn't be more pleased about entering into this innovative collaboration with UCB, which joins together leaders in academia and industry to advance pioneering research from the lab to the clinic," said Isaac T. Kohlberg, Harvard's Chief Technology Development Officer and head of its Office of Technology Development. "In furtherance of our mission to serve the public interest, Harvard has a deep and abiding commitment to collaborate with industry in ways that push the boundaries of translational research and seek to develop next generation therapies that will make a difference in the lives of patients. Our collaboration with UCB is an ideal example of how we advance these goals."

UCB will bring its expertise in antibody generation and medicinal chemistry into the alliance and will provide up to $6 million over two years to fund specific innovative research projects led by Harvard scientists. The collaboration focuses on central nervous system (CNS) and immunology, two key research domains for UCB.

For further information

Kristie Madara, U.S. Corporate Communications
T +1.770.970.8726,

France Nivelle, Global Communications
T +32.47.549.4001,

Antje Witte, Investor Relations, UCB
T +32.2.559.9414,

Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712,

Notes to the editor

About UCB

UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in more than 40 countries, the company generated revenue of euro 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB). The company's U.S. headquarters is located in Smyrna, Ga., a suburb of Atlanta.

About UCB NewMedicines

UCB NewMedicines is UCB's research and early development division, encompassing activities from discovery research through to clinical Proof of Concept. With scientific excellence and innovation at its core, UCB NewMedicines is focused on ensuring delivery of de-risked and differentiated molecules into full development. UCB NewMedicines™ is structured around two European 'research hubs', Braine-l'Alleud (Belgium) focusing on CNS diseases and Slough (U.K.) focusing on immunological disorders.

About Harvard University's Office of Technology Development

The Harvard Office of Technology Development (OTD) is responsible for all activities pertaining to the evaluation, patenting and licensing of new inventions and discoveries made at Harvard University and Harvard Medical School. OTD also serves to further the development of Harvard technologies through the establishment of sponsored research collaborations with industry. OTD's mission is to promote the public good by fostering innovation and translating new inventions made at Harvard into useful products available and beneficial to society.

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of employees.

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
2. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
3. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
4. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
7. Premier Micronutrient Launches Supplement for Hearing Health
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
10. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
11. Launches STD Social Networking Site Balancing Dating with Online Support Features
Post Your Comments:
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... UTRECHT , Nederland, November 26, 2015 ... --> Een nieuwe aanpak combineert ... van gevorderde kanker. ... -->      (Photo: ... van het Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... ) has ... Future Horizons and Growth Strategies in the ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> ) has announced the ... and Growth Strategies in the French Drugs ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices may ... one from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, there ... save the expense of having to replace NuvaRings more often than necessary. As such, ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... American Dental Association meeting in Washington D.C. revolved around the fact that proper dental ... health. The talk stressed the link between periodontal disease (more commonly referred to as ...
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, ... to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. ... dispense prescription medications. In doing so, it could help to prevent potential overdose ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... Health-E-minds, an innovative online platform for mental health and wellness consultation, has collaborated ... This partnership will bridge the knowledge gap experienced by parents and bring advice ...
Breaking Medicine News(10 mins):